Arrowhead Pharmaceuticals, Inc. (ARWR) financials
NASDAQ · Healthcare · Biotechnology · 711 employees · CEO Christopher R. Anzalone
- Price
- $59.90 -0.98%
- Market cap
- $8.46B
- Enterprise value
- $9.27B
- Last report
- Q3 '26 filed 2026-08-04
- Next report
- 2026-11-24 EPS est. -$1.52
Revenue (TTM)$669M+16.8% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-33.8%-15.0 pp vs a year agoOperating income -$226M
Net income (TTM)-$320M-115.6% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$75.1M-326.3% vs a year agoCapex $16.1M
Diluted EPS (TTM)-$2.24-72.3% vs a year agoSum of the last 4 quarters
Net cash$738M+294.4% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $8.46B EV $9.27B
- Revenue
- $669M Trailing 12 months
- Revenue growth
- -44% FY2026 consensus
- Profit margin
- -47.8% Net income / revenue, TTM
- P/E
- -26.7× Forward -17.0× (FY2026)
- P/S
- 12.6× Price / sales, TTM
- EV / EBITDA
- -69.4× TTM
- Free cash flow
- -$75.1M Trailing 12 months
- Net income
- -$320M Trailing 12 months
- Revenue estimate
- $464M FY2026 consensus
- Earnings
- 2026-11-24 Revenue est. $61.2M
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-08-04): revenue beat by 70.4%, EPS missed by 6.3%Revenue $75.3M vs $44.2M expected (+70.4%); EPS -$1.36 vs -$1.28 (-6.3%).
- Revenue growth slowing: 171.0% year on yearQ3 '26 revenue $75.3M, against an average of 5,187.5% over the four quarters before.
- Operating margin -33.8% (TTM), -15.0 pp on a year agoOperating income grew -109.7% while revenue grew 16.8%.
- Capex 2.4% of revenue (a year ago 6.9%)$16.1M invested in the last 4 quarters (-59.3% on a year earlier). Free cash flow -$75.1M.
- Diluted share count up 3.1% in a year143M diluted shares in Q3 '26, 139M a year earlier.
- Net cash $738MCash + short-term investments $1.6B, debt incl. leases $864M; a year ago net cash $187M.
Last quarter: Q3 '26
Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q3 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $75.3M | $27.8M | +171.0% |
| Gross margin | 100.0% | 100.0% | 0.0 pp |
| Operating income | -$170M | -$166M | -2.7% |
| Operating margin | -226.0% | -596.2% | +370.2 pp |
| Net income | -$194M | -$175M | -10.9% |
| Diluted EPS | -$1.36 | -$1.26 | -7.9% |
| Operating cash flow | -$177M | -$155M | -14.7% |
| Capex | $3.85M | $2.36M | +63.0% |
| Free cash flow | -$181M | -$157M | -15.4% |
| R&D | $198M | $162M | +22.1% |
| Stock-based compensation | $14.7M | $13M | +12.9% |
Reported vs consensus
2026-08-04| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $75.3M | $44.2M | +70.4% |
| EPS (as estimated) | -$1.36 | -$1.28 | -6.3% |
From the report of 2026-08-04 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyMargins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- -$59.1M
- Capex
- -$16.1M
- Buybacks
- $0
- Dividends
- $0
- Acquisitions
- $0
- Net debt issued
- $1.19B
- Stock-based compensation
- $70M
- Free cash flow
- -$75.1M
- Returned to shareholders / FCF
- 0.0%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | -26.7× | – | – |
| EV / EBITDA | -69.4× | 28.8× 1 of 5 years | 28.8× – 28.8× |
| EV / Sales | 13.8× | 188.6× | 5.7× – 864.4× |
| Price / FCF | -112.6× | 36.6× 2 of 5 years | 29.4× – 43.8× |
| Price / Book | 18.4× | 11.5× | 8.7× – 15.8× |
| FCF yield | -0.9% | -7.5% | -26.0% – 3.4% |
| Return on invested capital | -12.1% | -28.3% | -57.4% – 4.6% |
| Return on equity | -60.5% | -95.6% | -323.3% – -0.3% |
Analysts
Consensus target $101.56 (+69.5%)
range $46.00 – $126.00 · rating Buy
Strong buy0
Buy16
Hold6
Sell0
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $464M | -44.0% | -$3.52 | -28,781.2% | -17.0× | 12 |
| FY2027 | $330M | -28.9% | -$4.86 | -37.8% | -12.3× | 13 |
| FY2028 | $666M | +101.8% | -$2.81 | +42.1% | -21.3× | 8 |
| FY2029 | $1.15B | +72.3% | -$0.74 | +73.8% | -81.4× | 5 |
| FY2030 | $2.04B | +78.1% | $4.41 | +698.7% | 13.6× | 3 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 228 figures Arrowhead Pharmaceuticals, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $27.8M | $33.1M | -16.0% | $17.7M | $11.4M | +55.2% |
| Accounts Receivable, after Allowance for Credit Loss | $5.8M | $9.7M | -40.2% | $6.82M | $0 | – |
| Accounts Receivable, after Allowance for Credit Loss, Current | $8.56M | $9.7M | -11.8% | $6.82M | $0 | – |
| Accrued Income Taxes, Current | $0 | – | – | $20.8M | $0 | – |
| Accrued Liabilities, Current | $86.2M | $64.8M | +32.9% | $90.4M | $63M | +43.5% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $97.2M | $74.2M | +31.0% | $80.2M | $58M | +38.2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$1.23M | $5.36M | -123.0% | $6.44M | $4.75M | +35.6% |
| Additional Paid in Capital, Common Stock | $2.44B | $2.12B | +15.2% | $2.14B | $1.81B | +18.5% |
| Adjustments to Additional Paid in Capital, Warrant Issued | $100M2026-03-31 | – | – | $25M | – | – |
| Amortization of Debt Issuance Costs | $766K | $0 | – | – | – | – |
| Amortization of Intangible Assets | $400K | $400K | 0.0% | $1.7M | $1.7M | 0.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 14.7M | 5.95M | +146.6% | 5.02M | 4.74M | +6.0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $14.9M | $13M | +14.0% | $63.4M | $74M | -14.3% |
| Assets | $2.11B | $1.38B | +53.0% | $1.39B | $1.14B | +21.5% |
| Assets, Current | $1.67B | $947M | +76.5% | $951M | $695M | +36.7% |
| Assets, Fair Value Disclosure | $1.58B | – | – | – | – | – |
| Capital Expenditures Incurred but Not yet Paid | $750K | -$12K | +6,350.0% | $277K | $4.21M | -93.4% |
| Cash and Cash Equivalents, Fair Value Disclosure | $32.2M | – | – | – | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $54.8M | $130M | -57.8% | $227M | $103M | +120.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | -$134M | -$56M | -139.7% | $124M | -$12.4M | +1,101.9% |
| Class of Warrant or Right, Exercise Price of Warrants or Rights | – | – | – | $0.002024-11-25 | – | – |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | – | – | – | 917K2024-11-25 | – | – |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 290M | 290M | 0.0% | 290M | 290M | 0.0% |
| Common Stock, Shares, Issued | 144M | 138M | +4.1% | 136M | 124M | +9.1% |
| Common Stock, Shares, Outstanding | 141M | 138M | +2.2% | 136M | 124M | +9.1% |
| Common Stock, Value, Issued | $237K | $230K | +3.0% | $231K | $217K | +6.5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $15.6M | -$3.41M | +556.6% | $31.7M | -$10.2M | +411.2% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$196M | -$174M | -12.6% | -$141M2021-09-30 | -$84.1M | -67.5% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | -$181M | -$178M | -1.7% | $31.8M | -$602M | +105.3% |
| Contract with Customer, Asset, after Allowance for Credit Loss, Current | $10.2M | – | – | – | – | – |
| Contract with Customer, Liability | $2.4M2025-09-30 | $0 | – | $2.4M | $0 | – |
| Contract with Customer, Liability, Current | $94.6M | $23M | +311.7% | $2.4M | $0 | – |
| Contract with Customer, Liability, Noncurrent | $31.7M | $0 | – | $02023-09-30 | $56M | -100.0% |
| Contract with Customer, Liability, Revenue Recognized | -$46.6M | -$27.6M | -68.8% | – | – | – |
| Convertible Debt | $683M | – | – | – | – | – |
| Convertible Debt, Noncurrent | $683M | – | – | – | – | – |
| Current Federal Tax Expense (Benefit) | – | – | – | $21.4M | $148K | +14,386.5% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $35K | -$3.29M | +101.1% |
| Current Income Tax Expense (Benefit) | – | – | – | $21.4M | -$2.77M | +874.1% |
| Current State and Local Tax Expense (Benefit) | – | – | – | -$56K | $375K | -114.9% |
| Debt Securities, Available-for-sale | $1.55B | $771M | +100.8% | $693M | $578M | +19.8% |
| Debt Securities, Available-for-sale, Amortized Cost, Current | $1.55B | $769M | +102.1% | $690M | $577M | +19.5% |
| Debt Securities, Available-for-sale, Current | $1.55B | $771M | +100.8% | $693M | $578M | +19.8% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year | $605M | $225M | +169.6% | – | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $224M2025-09-30 | $578M | -61.2% | $224M | $578M | -61.2% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Assets, Deferred Income | $171M2025-09-30 | $81.6M | +110.0% | $171M | $81.6M | +110.0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $1.03M2025-09-30 | $1.38M | -25.3% | $1.03M | $1.38M | -25.3% |
| Deferred Tax Assets, Gross | $563M2025-09-30 | $473M | +19.0% | $563M | $473M | +19.0% |
| Deferred Tax Assets, Net | $02025-09-30 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Operating Loss Carryforwards | $70.9M2025-09-30 | $103M | -31.0% | $70.9M | $103M | -31.0% |
| Deferred Tax Assets, Other | $948K2025-09-30 | $2.84M | -66.7% | $948K | $2.84M | -66.7% |
| Deferred Tax Assets, Tax Credit Carryforwards | $48.9M2025-09-30 | $85.4M | -42.8% | $48.9M | $85.4M | -42.8% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $4.25M2025-09-30 | $4.08M | +4.3% | $4.25M | $4.08M | +4.3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $9.18M2025-09-30 | $11M | -16.4% | $9.18M | $11M | -16.4% |
| Deferred Tax Assets, Valuation Allowance | $498M2025-09-30 | $449M | +10.8% | $498M | $449M | +10.8% |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02